The ROSELLA trial showed relacorilant plus nab-paclitaxel improved progression-free survival in platinum-resistant ovarian cancer patients. Relacorilant reduced disease progression risk by 30% and ...

with or without Avastin (bevacizumab), for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer. At final analysis, data from the study showed that the Keytruda plus ...

data from the ROSELLA study suggested that the combo of relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer.

will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology ...

a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer. BELLA is a single-arm, open-label trial with ...

ARTISTRY-7 trial data showed nemvaleukin plus Keytruda did not significantly improve overall survival in platinum-resistant ovarian cancer. Mural Oncology will halt nemvaleukin’s development for ...